Deucravacitinib is a potent Type I IFN inhibitor and indirectly inhibits IFNγ; however, infection rates are low relative to JAK1,2,3 inhibitors due to optimized dosing that sufficiently controls inflammation without complete pathway inhibition (26, 28). This evidence concerns the gene IFNG and infection.